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Abstract: Mitochondria play important roles in cellular energy metabolism, free radical generation, and apoptosis. 
Mitochondrial DNA has been proposed to be involved in carcinogenesis because of its high susceptibility to mutations and 
limited repair mechanisms in comparison to nuclear DNA. Breast cancer is the most frequent cancer type among women in 
the world and, although exhaustive research has been done on nuclear DNA changes, several studies describe a variety of 
mitochondrial DNA alterations present in breast cancer. In this review article, we to provide a summary of the mitochondrial 
genomic alterations reported in breast cancer and their functional consequences.
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Introduction
Mitochondria are cytoplasmic semi-autonomously functioning organelles, which contain a resident 
genome, and replicate, translate and transcribe their own DNA (mtDNA) (Anderson et al. 1981; 
Taanman, 1999). Each organelle contains 2–10 copies of mtDNA molecules, and each human cell 
contains thousands of copies which varies in number with the cell type (Chen and Butow, 2005). 
Mitochondria are responsible for generating approximately 90% of cellular ATP through the process 
of oxidative phosphorylation (OXPHOS) and play essential roles in cellular energy metabolism, free 
radical generation, and programmed cell death (Chan, 2006). Human mtDNA is a circular double-
stranded molecule consisting of 16.571bp encoding 13 polypeptides that constitute respiratory chain 
complexes, as well as 2 rRNAs and a set of 22 tRNAs for mitochondrial protein synthesis (Anderson 
et al. 1981; Andrews et al. 1999). The mtDNA undergoes replication using a different origin for each 
of the two strands, the purine (guanine) abundant H-strand, and the pyrimidine (cytosine) abundant 
L-strand. The displacement (D)-loop encompasses 1124 bp, between nt 16024 and nt576, and is the 
only major non-coding region of the mitochondrial genome. It contains the origin of replication for 
H-strand synthesis, both mitochondrial transcription promoters (Lutz et al. 1997; Taanman, 1999), 
and has a triple-stranded DNA structure that is more sensitive to oxidative damage due to the expo-
sure of the displaced single strand in the arrested replication intermediate (Clayton, 2000). It is also 
the attachment point of the mtDNA molecule to the mitochondrial inner membrane (Clayton, 1992). 
Replication is initiated at the H-strand origin, and proceeds to two-thirds around the genome until 
the L-strand origin is exposed, thus initiating L-strand synthesis (Fig. 1). Unlike nuclear DNA (nDNA), 
mtDNA may replicate more than once during each cell cycle, or not at all. Moreover, mtDNA may 
replicate in non-dividing cells. Compared with nDNA, mtDNA is more vulnerable to damages due 
to the lack of protective histones, limited DNA repair capacity, lack of introns, and is exposed con-
tinuously to endogenous reactive oxygen species (ROS) (Chen and Butow, 2005; Higuchi, 2007). 
Since all of the genes in mtDNA are crucial for biogenesis and bioenergetics function of mitochondria, 
any mtDNA alteration may result in impairment of OXPHOS and enhanced ROS production, which 
in turn, may accelerate the rate of mtDNA mutations (Higuchi, 2007; Lee and Wei, 2005). Mutated 
mtDNA and wild-type mtDNA molecules can coexist in the same cell, tissue or organ in a state called 
heteroplasmy. Mitochondria containing only mutated DNA (or only wild-type mtDNA) are called 
homoplasmic. The study of genotype-phenotype relationships in mitochondrial diseases has shown 
clearly the existence of a “phenotypic threshold effect”, which can be characterized by the 200
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following: (i) a low proportion of wild-type 
mtDNA coexisting with mutated mtDNA allows 
a normal phenotype to be maintained, but (ii) a 
small decrease in this proportion below a threshold 
value alters the phenotype.
Mitochondrial DNA Mutations 
and Breast Cancer
Mitochondrial defects have long been suspected 
to play an important role in the development and 
progression of cancer. Over 70 years ago, Warburg 
pioneered the research on mitochondrial respiration 
alterations in the context of cancer and proposed 
a mechanism to explain how they evolve during 
the carcinogenic process. He hypothesized that a 
key event in carcinogenesis involved an “injury” 
to the respiratory machinery, resulting in compen-
satory increases in glycolytic ATP production. Due 
to the inherent inefﬁ  ciency of glycolytic ATP gen-
eration, this represents a unique metabolic state of 
the malignant cells and would require high con-
sumption of glucose to fulfil cellular energy 
requirements. Therefore, cancer cells actively 
metabolize glucose and produce excessive lactic 
acid while, at the same time, consume oxygen via 
OXPHOS. Warburg called this phenomenon 
“aerobic glycosysis” (Warburg, 1930; Warburg, 
1956). Wargburg´s observation stimulated many 
investigators to analyse mitochondrial function in 
tumor cells. Since then, many studies have reported 
mtDNA abnormalities in colorectal, bladder, head 
and neck, lung, pancreatic, gastric, hepatic, renal, 
ovarian and breast cancers and haematological 
diseases among others (Brandon et al. 2006; 
Chatterjee et al. 2006). The role of mtDNA muta-
tions in tumor development is still unclear and only 
a subset of the mutations observed are predicted 
to have a relevant effect. The mtDNA mutations 
could arise either in the germ line and predispose 
to cancer (oncogene germline mutations), or in the 
mtDNA of the tissues (tumor-speciﬁ  c somatic 
mutations) and participate in the tumor progression 
process. Breast cancer is the most commonly diag-
nosed cancer of women and the second leading 
cause of cancer deaths among women. On one 
hand, inherited mutations in the breast cancer 
susceptibility genes, BRCA1 and BRCA2, 
predispose to breast, ovarian, and other types of 
cancer (Thompson and Easton, 2004). On the other 
hand, according to epidemiological studies, pro-
longed exposure to estrogen, including an earlier 
menarche, and prolonged reproductive stimulation 
during lifetime, signiﬁ  cantly associate with an 
increased risk of sporadic breast cancer (Oldenburg 
et al. 2007). Until recently, research has focused 
on nDNA changes, while alterations in mtDNA 
were largely ignored. Nowadays, there has become 
increasing awareness that mtDNA mutations might 
be more worthy of the kind of scrutiny once applied 
only to nDNA. Several studies indicate that most 
breast cancers harboured mtDNA that contains a 
variety of alterations including point mutations 
(germline and/or somatic), mtDNA depletion and 
microsatellite instability (MSI).
Germline mtDNA mutations 
in breast cancer
Several mtDNA population polymorphisms have 
been associated with increased breast cancer risk, 
stressing the importance of germline mtDNA muta-
tions in the aetiology of certain cancers. One of 
those mutations is the germline T16189C substitu-
tion in one of the poly (C)-T-poly(C) structural 
motifs within the D-loop region. The T to C change 
in the wild-type (C5TC4) generates a long run of 
C residues considered to be a source of enhanced 
instability. Some authors have associated this vari-
ant with susceptibility to endometrial cancer 
(Liu et al. 2003) and breast cancer (Wang et al. 
2006). It has been proposed as a potential marker 
for cancers with metabolic risk factor, since is has 
been associated signiﬁ  cantly with type II diabetes 
(Poulton et al. 2002) and it has long been known 
that diabetes mellitus is an important epidemio-
logic risk factor for endometrial and breast cancers 
(Weiderpass et al. 1997). Another intensively 
studied change is a G10398A polymorphism 
(codon 114) which results in a non-conservative 
amino acid substitution of threonine (encoded by 
the A allele) for alanine (encoded by the G allele), 
within the NADH Dehydrogenase (ND3) subunit 
of Complex I. The 10398A allele was linked to 
increased risk for invasive breast cancer in both 
pre- and post-menopausal African-American 
women, although the mechanism underlying this 
relationship remains to be elucidated (Canter et al. 
2005). Since Complex I is a key component of the 
mitochondrial electron transport chain, the amino 
acid change may increase the rate of electron leak-
age and ROS generation, contributing to mtDNA 
and nDNA mutations and cumulative mitochondrial 
dysfunction which could contribute to disease. 201
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Many factors, other than the mtDNA G10398A 
polymorphism are likely to be important in the 
development and progression of invasive breast 
cancer in African-American women (Hall et al. 
2005). In a very recent study Bai et al. showed that 
10398A   G, 9055G   A and 16519T   C may 
increase the risk of developing breast cancer or are 
in linkage disequilibrium with functional variants 
that increase this risk. However, 3197T   C and 
13708G   A have a protective effect or are in 
linkage disequilibrium with protective variants. In 
addition, this group studied mtDNA haplogroups 
and ﬁ  nd an important role in disease expression. 
Clusters of mtDNA polymorphisms constitute 
haplogroups that have been extensively used to 
track human migrations and to explore variation 
in disease phenotypes. Within the 10 European 
haplogroups observed there was much higher pro-
portion of breast cancer cases compared with 
controls in haplogroup K (deﬁ  ned by 29 polymor-
phic sites), whereas opposite result is observed for 
haplogroup U. Therefore, mitochondrial genetic 
background would play a very important role in 
modifying the individual´s risk to breast cancer 
(Bai et al. 2007).
Somatic mtDNA mutations 
in breast cancer
While interpretation of linking germline mtDNA 
mutations to cancer can be controversial due to 
the high background frequency of functional 
mtDNA polymorphisms, studies of somatic 
mtDNA mutations could be easy to handle since 
the cancer cell should have the neoplastic mtDNA 
mutation while the normal tissue should not. Par-
rella et al. determined the frequency and distribu-
tion of mtDNA mutations in 18 primary breast 
tumors by direct sequencing. 42% were deletions 
or insertions within the D-loop, 58% were single-
base substitutions in the coding (ND1, ND4, ND5 
and cytochrome b genes) or non-coding regions 
(D-loop). In 25% of the cases the mutations 
detected in the coding region led to amino acid 
substitutions in the protein sequence. Identical 
changes were found in breast nipple ﬁ  ne-needle 
aspirate fluid (FNA) and metastatic positive 
lymph nodes (Parrella et al. 2001). Zhu et al. 
described 45 somatic mutations in breast cancer 
tissue and in nipple aspirate ﬂ  uid, 35 of those 
were at unique loci. Mutations at nine of the loci 
(seven in the D-loop and two in non-D loop areas) 
have been reported in other cancer types suggesting 
that these sites were susceptible to mutation in a 
variety of human malignancies (Bianchi et al. 
1995; Polyak et al. 1998; Fliss et al. 2000; Parrella 
et al. 2001). At the same time, and although not 
all the FNA had sufﬁ  cient tumor cells to detect 
the mutations identiﬁ  ed in the tissue, FNA repre-
sent a promising non-invasive approach to obtain 
breast epithelial cells (Zhu et al. 2005). Tan et al. 
used a combination of temporal temperature gel 
electrophoresis and direct DNA sequencing to 
screen the complete mitochondrial genome for 
mutations in 19 sets of paired normal and breast 
tumor tissues. Somatic mutations were identiﬁ  ed 
in 74% of the patients. The bulk of the mutations 
(82%) were restricted to the D-loop region rein-
forcing, again, the ﬁ  ndings that this region is a 
mutation hot spot (Tan et al. 2002). D-loop 
alterations may interfere with the sequence in the 
promoter areas and modify the afﬁ  nity to the 
inducers or modulators of mtDNA transcription, 
thus putatively resulting in changes in the rate of 
transcription, RNA primer synthesis, and mtDNA 
replication (Clayton, 2000; Shadel and Clayton, 
1997). Indeed, mtDNA content of hepatocellular 
carcinoma and breast tumors was signiﬁ  cantly 
decreased in 71% and 88% of patients with 
D-loop region mutations (Lee et al. 2004; Yu et al. 
2007). Data suggest a possible contribution of 
mtDNA D-loop mutation to alterations in mtDNA 
level. A representation of mtDNA point mutations 
in breast cancer, described in the literature, is 
shown in Figure 1. The most frequently observed 
mtDNA mutation in human tissues is the 
∆mtDNA
4977 deletion. This mutation affects genes 
encoding 7 polypeptide components of the mito-
chondrial respiratory chain, and 5 of the 22 tRNAs 
necessary for mitochondrial protein synthesis 
(Porteous et al. 1998). The ∆mtDNA
4977 mutation 
was initially reported as occurring in one out of 
seven breast cancer samples (Bianchi et al. 1995). 
Further studies reported a different pattern of 
∆mtDNA
4977 mutation in tumors compared to 
normal tissue (Dani et al. 2004; Tseng et al. 2006). 
Recently, high sensitivity and speciﬁ  city assays 
show that this ∆mtDNA
4977 mutation is ubiquitous 
in both tumor and non-tumor tissues of both breast 
cancer and benign breast disease (Ye et al. 2007). 
Bibliographic data do not support the notion that 
the ∆mtDNA
4977 mutation plays a major role in 
breast carcinogenesis (Schwartz et al. 2006; 
Tseng et al. 2006; Zhu et al. 2004). The amount 202
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of ∆mtDNA
4977 mutation that accumulates may 
not be sufﬁ  cient, by itself, to cause a signiﬁ  cant 
defect or dysfunction in breast cancer cells (Ye 




4576) require further 
investigations. The ﬁ  rst two have been found to 
be more frequent in cancerous than in adjacent 
histologically normal breast specimens, but were 
also identified in normal tissue from women 
without breast cancer. The last one, was detected 
in 13% of histologically normal specimens from 
a breast with cancer but in 77% of cancer speci-
mens from the same breast (Zhu et al. 2004).
Somatic mtDNA mutations 
could not be what they look like
To learn more about the nature of somatic mtDNA 
mutations in tumors, Brandon et al. recruited all 
data on somatic mtDNA, found in different types of 
cancers, and compared them with the mtDNA vari-
ant sites contained in their global human mtDNA 
database of 1920 complete mtDNA sequences plus 
532 coding region mtDNA sequences (Brandon 
et al. 2006; Brandon et al. 2005). Surprisingly, 72% 
of the somatic mtDNA mutations were also 
sequence variants in population specific hap-
logroups database. A clear example is the nt13708 
Figure 1. mtDNA point mutations in breast cancer described in the literature. Every tick represents a mutation locus detected. 
Abbreviations: 12S: 12S ribosomal RNA; 16S: 16S ribosomal RNA; ND1, 2, 4, 5 and 6: NADH dehydrogenase subunit 1, 2, 4, 5 and 6; 
ATPase: ATP Synthase F0 subunit 8; COI, II and III: cytochrome c oxidase subunit I, II and III; Cyt B: cytochrome b; OH: H-strand replication 
origin; OL: L-strand replication origin.203
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G to A missense mutation in ND5 (A458T), 
reported in breast cancer tumor (Parrella et al. 
2001). In African L0-L3, Asian M, and at the base 
of Eurasian N mtDNAs, the nt13708 is a G (458A). 
However, at the root of European haplogroup J, 
and in important sublineages of the European X 
and Asian B haplogroups, the nt13708 is an A 
(458T). Therefore, the tumor-speciﬁ  c mutation 
results in the conversion of the mtDNA sequence 
to a Eurasian-like allele. Authors suggest that can-
cer cells acquire some of the same functional 
mtDNA mutations that confer adaptive advantages 
in population haplotypes, as cells migrate into new 
environments. They consider two main classes of 
mtDNA mutations: tumorigenic mutations and 
adaptive mutations. The ﬁ  rst ones are found only 
in tumors and lead to a relatively severer deleteri-
ous effects on mitochondrial metabolism and ROS 
production. The second ones, alter the same 
nucleotides as population variants and may have 
a milder impact on mitochondrial OXPHOS, and 
help the tumors to adapt to adverse environments. 
Moreover, these two different classes of somatic 
mutations might arise at different times, being 
tumorigenic mutations with advantage in the initial 
phases of tumor growth. In this early stage, tumor 
is hypoxic and thus can tolerate OXPHOS deﬁ  -
ciency since its generating ATP by glycolysis. By 
contrast, adaptive mtDNA mutations may be more 
advantageous when the tumor becomes vascular-
ized and/or invade new environments as it 
metastasizes (Brandon et al. 2006). Therefore, 
understanding mtDNA variations in cancer cells 
provide new major insights into the aetiology of 
solid tumors.
Mitochondrial DNA Copy Number 
in Breast Cancer
The evidence regarding the role of mtDNA content 
in mammary tumorigenesis, and its relationship 
with clinico-pathological factors and patient out-
come, is limited. It has been shown that a reduction 
of mtDNA content occurred in breast tumors, but 
this proportion was greater for papillary thyroid 
carcinomas, suggesting that changes in mtDNA 
content during carcinogenesis may be regulated in 
a tumor-speciﬁ  c manner (Mambo et al. 2005). In 
a study of 60 pairs of tumors, and corresponding 
no tumorous breast tissues, results indicated that 
63% of the tumors had a significant lower 
mtDNA content compared to their corresponding 
non-tumorous breast tissue (Tseng et al. 2006). The 
analysis of 59 pairs of breast tumors and adjacent 
non-tumorous tissues has shown recently that 78% 
of the cases carried a reduction of mtDNA content 
compared to the corresponding non-tumorous cells. 
It has been well documented that ER-negative 
breast tumors have signiﬁ  cantly more aggressive 
clinical behaviour and are unresponsive to anti-
estrogenic therapy ((EBCTCG). 2005).A reduced 
mtDNA copy number tends to have a signiﬁ  cant 
correlation with ER status (Yu et al. 2007). Several 
lines of evidence have demonstrated that altered 
mtDNA content may lead to a functional defect in 
oxidative phosphorylation and affect the respira-
tory activity of the cells, ultimately changing their 
growth behaviour (Isidoro et al. 2004). The mtDNA 
level reduction can be due to: (i) mtDNA D-loop 
mutations and (ii) dysfunction of p53 gene, among 
other causes. In the ﬁ  rst case, and as it has been 
mentioned before, there is a possible contribution 
of mtDNA D-loop mutations to alterations in 
mtDNA level. In the second case, it has been 
reported that the p53 plays an important role in 
maintaining mitochondrial genetic stability via the 
interaction with mtDNA polymerase γ(Achanta 
et al. 2005; Heyne et al. 2004). Loss of p53 could 
lead to increased mtDNA vulnerability to exoge-
nous and endogenous damage, subsequently ele-
vating frequency of mtDNA mutations (as for 
example D-loop mutations), and therefore mtDNA 
depletion.
Mitochondrial DNA and 
Microsatellite Instability (MSI) 
in Breast Cancer
Microsatellites are short tandem repeats of 
sequence motifs, usually ranging from one to ﬁ  ve 
DNA bases. MSI is the change of length in any 
such stretch, due to either insertions or deletions 
of repeating units in a microsatellite, within tumor 
DNA compared to that of normal tissue. Nuclear 
MSI is thought to result from a defect in the mis-
match repair system, which leads to failure in 
correction of the slippage errors made by DNA 
polymerases during replication. Nuclear MSI was 
ﬁ  rst described in colorectal cancer (Thibodeau 
et al. 1993) and subsequently observed in most 
cancers (Lawes et al. 2003). However, instability 
in these terms of the mitochondrial genome, which 
is also subject to genetic alterations in cancer cells, 
(Bianchi et al. 2001; Richard et al. 2000) is worse 204
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characterized, and the responsible mechanisms of 
generation are still unclear. Wang et al. studied 12 
candidate microsatellite regions within the entire 
mtDNA genome of a series of primary cervical 
(71), endometrial (62), ovarian (73) and breast 
cancer (51) patients. One relevant ﬁ  nding of this 
study was that the poly (C)-T-poly(C) structural 
motifs in the D-loop seem to be prone to MSI 
(Wang et al. 2006). The wild-type sequences 
(according to revised Cambridge sequence, http://
www.mitomap.org/) of these markers are C7TC5 
at nt303, C5TC4 at nt956 and C5TC4 at nt16184 
and their instability patterns are different. At nt303, 
alterations were detected upstream to the T residue, 
the mtMSI manifestation being (C)7-11 TC5. At 
nt16184, mtMSI presents a particular pattern, 
consequential to a T to C germline substitution at 
nt16189, which has been discussed before. The 
nt956 showed both types of mtMSI. Authors found 
that mtMSI had different proﬁ  les and frequency in 
the four types of cancer, suggesting that different 
tumors may have generated different extents of 
mtMSI during carcinogenesis (Wang et al. 2006). 
On the contrary, no microsatellites in the coding 
region containing poly (A), poly (T) and poly (C) 
were unstable. It has been suggested that polyC-
instability might be related to a highly mitogenic 
history and to progressive tumors, in particular, 
tumors that had already metastasized at the time 
of diagnosis. Nevertheless, mutations in the (C)n 
non-coding repeats could not be selected during 
tumor progression, but associated with higher 
replication rates of mtDNA in tumors because of 
their inherent mutability (Schwartz et al. 2006). 
Although mtMSI hot spots have been identiﬁ  ed, it 
remains a challenge to address their functional 
impact.
Homoplasmy/Heteroplasmy
Published data show that the majority of somatic 
mtDNA mutations are homoplasmic, indicating 
that mutant mtDNA had become dominant in the 
cancer cells, although the mechanism(s) for the 
development of mtDNA homoplasmy in cancer 
tissue is controversial. The lack of histones protec-
tion, limited repair ability, and close proximity to 
the electron transport chain make mtDNA far more 
susceptible to DNA damaging agents (ROS and/or 
certain anticancer drugs and radiation). Since such 
induced mutations do not involve all copies of 
mtDNA, an initial mutation is heteroplasmic with 
the mutated mtDNA being the minority. Two 
models, classic selection and random genetic drift, 
have been developed to explain the expansion of 
homoplasmy in tumors (Cavelier et al. 2000; Coller 
et al. 2001). The ﬁ  rst interpretation is that expan-
sion of the mutation was driven by strong selection 
for the mutant phenotype (Fig. 2). In this context, 
if a mutation leads to a disadvantage in cell growth 
or survival, such mutation is deemed to diminish. 
Conversely, if a mutation confers cell growth/
survival advantage or facilitates mtDNA replica-
tion, such a mutation is likely to survive the selec-
tion and emerge as a heteroplasmic mutation. 
Depending on the degree of growth/survival advan-
tage, cells carrying the mtDNA mutation may 
eventually become dominant and evolve to estab-
lish a homoplasmic mutant state. It is possible that 
mtDNA mutations cause a functional change that 
compromises the efﬁ  ciency of the electron trans-
port chain, leading to electron ﬂ  ow bifurcation and 
increased generation of ROS. A moderate increase 
of ROS has been found to stimulate cellular 
proliferation and mitochondrial biogenesis (Liu 
et al. 2002). The increase in ROS production may 
cause further damage to both mtDNA and nDNA, 
leading to cancer development, genetic instability, 
and disease progression. The second model, pub-
lished by Coller et al. conclude that human tumors 
are expected to contain homoplasmic mitochon-
drial mutations based only on random mutagenesis 
and segregation of mtDNA (Coller et al. 2001). By 
using extensive computer modelling programs, 
authors show that when the mtDNA mutation 
occurs in a tumor progenitor cell, homoplasmy can 
be archived entirely by chance through unbiased 
mtDNA replication and sorting during cell division, 
without selection for physiological advantage. 
They estimate the mtDNA mutation rate as 7–10 
mutations per base pair per generation, and the 
number of generations of cell growth experienced 
by a carcinoma founder cell as 600. Model predicts 
that 58% of tumors contain at least one homoplasmic 
point mutation. This fraction is close to the 
experimental observation that 48% of tumors from 
which essentially the entire mitochondrial genome 
was sequenced, contain at least one homoplasmic 
mtDNA mutation (Fliss et al. 2000; Polyak et al. 
1998). Moreover, this model also correctly predicts 
the distribution of the number of mutations per 
tumor, and it is relatively stable with respect to 
changes in parameters such as the number of mito-
chondria per cell, the mutation rate and the number 205
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of generations. Therefore it could be argued that, 
some mitochondrial mutations may provide a 
selective advantage for the carrier mtDNA copy of 
the host cell. However, although selection may 
occur in some instances, it is not necessarily the 
only cause. A large fraction of human tumors are 
expected to be homoplasmic for mtDNA point 
mutations based solely on reported mitochondrial 
mutant fractions and cell growth kinetics of tumors. 
Whereas it cannot be excluded the possibility that 
selection occurs in a subset of tumors, physiolog-
ical advantage or a role for mitochondrial muta-
tions in tumorigenesis, may not be the only cause 
to explain the existence of homoplasmy or its 
observed frequency. Finally, although the mito-
chondrial and nuclear genomes are physically 
distinct, there is constant communication between 
the two genomes to carry out many of the mito-
chondrial functions. The identiﬁ  cation of a large 
number of genes whose expression is inﬂ  uenced 
by mitochondrial function provides pathways 
affected by the impairment of mitochondria in 
pathological conditions (Delsite et al. 2002). And 
this impairment would be, at the same time, related 
to the grade of mitochondrial heteroplasmy. In this 
context we have to consider that phenotypic 
manifestations of mitochondrial defects occur 
when a threshold level is exceeded. Depending on 
the gene affected by the mutation in mtDNA, and 
the grade of heteroplasmy, complementation can 
occur at different levels: transcription, translation, 
enzyme assembly and activity, mitochondrial ATP 
synthesis, cell activity and, ﬁ  nally, organ function 
(Rossignol et al. 2003).
Summary
The presence of mtDNA mutations in cancer is 
consistent with the intrinsic susceptibility of 
mtDNA to damage and constitutive oxidative stress. 
Figure 2. The classic selection method used to explain the expansion of mtDNA homoplasmy in tumors (in the random genetic drift, human 
tumors are expected to contain homoplasmic mitochondrial mutations based only on random mutagenesis and segregation of mtDNA).206
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The central role of the mitochondria in energy 
production, ROS generation and apoptosis regula-
tion, combined with a variety of mtDNA alterations 
(germline and/or somatic point mutations/deletions, 
mtDNA depletion and MSI) could provide rational 
explanation for many of the metabolic features of 
solid tumor biology. At the same time genetic back-
ground (mtDNA haplogroups and variations) is 
important in modifying the individual’s risk of 
cancer. Therefore, the aetiology of the protective 
or detrimental effect of variants/mutations should 
be considered in the context of mtDNA hap-
logroups. Moreover, the grade of heteroplasmy and 
the phenotypic threshold effect may play a major 
role in the impairment of mitochondria in patho-
logical conditions. Finally, mtDNA is not under the 
stringent control of the cell cycle and intergenomic 
signalling pathways in carcinogenesis could be 
exploited in cancer therapeutics.
References
Achanta, G., Sasaki, R., Feng, L. et al. 2005. Novel role of p53 in maintain-
ing mitochondrial genetic stability through interaction with DNA Pol 
gamma. Embo. J., 24:3482–3492.
Anderson, S., Bankier, A.T., Barrell, B.G. et al. 1981. Sequence and 
organization of the human mitochondrial genome. Nature, 
290:457–465.
Andrews, R.M., Kubacka, I., Chinnery, P.F. et al. 1999. Reanalysis and 
revision of the Cambridge reference sequence for human mitochon-
drial DNA. Nat. Genet., 23:147.
Bai, R.K., Leal, S.M., Covarrubias, D. et al. 2007. Mitochondrial 
genetic background modifies breast cancer risk. Cancer Res., 
67:4687–4694.
Bianchi, M.S., Bianchi, N.O. and Bailliet, G. 1995. Mitochondrial DNA 
mutations in normal and tumor tissues from breast cancer patients. 
Cytogenet. Cell. Genet., 71:99–103.
Bianchi, N.O., Bianchi, M.S. and Richard, S.M. 2001. Mitochondrial 
genome instability in human cancers. Mutat. Res., 488:9–23.
Brandon, M., Baldi, P. and Wallace, D.C. 2006. Mitochondrial mutations 
in cancer. Oncogene, 25:4647–4662.
Brandon, M.C., Lott, M.T., Nguyen, K.C. et al. 2005. MITOMAP: a human 
mitochondrial genome database--2004 update. Nucleic Acids Res., 
33:D611–613.
Canter, J.A., Kallianpur, A.R., Parl, F.F. et al. 2005. Mitochondrial DNA 
G10398A polymorphism and invasive breast cancer in African-
American women. Cancer Res., 65:8028–8033.
Cavelier, L., Jazin, E., Jalonen, P. et al. 2000. mtDNA substitution rate and 
segregation of heteroplasmy in coding and noncoding regions. 
Hum. Genet., 107:45–50.
Clayton, D.A. 1992. Structure and function of the mitochondrial genome. 
J. Inherit Metab. Dis., 15:439–447.
Clayton, D.A. 2000. Transcription and replication of mitochondrial DNA. 
Hum. Reprod., 15(2):11–17.
Coller, H.A., Khrapko, K., Bodyak, N.D. et al. 2001. High frequency of 
homoplasmic mitochondrial DNA mutations in human tumors can 
be explained without selection. Nat. Genet., 28:147–150.
Chan, D.C. 2006. Mitochondria: dynamic organelles in disease, aging, and 
development. Cell., 125:1241–1252.
Chatterjee, A., Mambo, E. and Sidransky, D. 2006. Mitochondrial DNA 
mutations in human cancer. Oncogene, 25:4663–4674.
Chen, X.J. and Butow, R.A. 2005. The organization and inheritance of the 
mitochondrial genome. Nat. Rev. Genet., 6:815–825.
Dani, M.A., Dani, S.U., Lima, S.P. et al. 2004. Less DeltamtDNA4977 
than normal in various types of tumors suggests that cancer 
cells are essentially free of this mutation. Genet. Mol. Res., 
3:395–409.
Delsite, R., Kachhap, S., Anbazhagan, R. et al. 2002. Nuclear genes involved 
in mitochondria-to-nucleus communication in breast cancer cells. 
Mol. Cancer, 1:6.
EBCTCG, E. B. C. T. C. G. 2005. Effects of chemotherapy and hormonal 
therapy for early breast cancer on recurrence and 15-year survival: 
an overview of the randomised trials. Lancet, 365:1687–1717.
Fliss, M.S., Usadel, H., Caballero, O.L. et al. 2000. Facile detection of 
mitochondrial DNA mutations in tumors and bodily ﬂ  uids. Science, 
287:2017–2019.
Hall, I.J., Moorman, P.G., Millikan, R.C. et al. 2005. Comparative analysis 
of breast cancer risk factors among African-American women and 
White women. Am. J. Epidemiol., 161:40–51.
Heyne, K., Mannebach, S., Wuertz, E. et al. 2004. Identiﬁ  cation of a puta-
tive p53 binding sequence within the human mitochondrial genome. 
FEBS Lett, 578:198–202.
Higuchi, M. 2007. Regulation of mitochondrial DNA content and cancer. 
Mitochondrion, 7:53–57.
Isidoro, A., Martinez, M., Fernandez, P.L. et al. 2004. Alteration of the 
bioenergetic phenotype of mitochondria is a hallmark of breast, 
gastric, lung and oesophageal cancer. Biochem. J., 378:17–20.
Lawes, D.A., SenGupta, S. and Boulos, P.B. 2003. The clinical importance 
and prognostic implications of microsatellite instability in sporadic 
cancer. Eur. J. Surg. Oncol., 29:201–212.
Lee, H.C., Li, S.H., Lin, J.C. et al. 2004. Somatic mutations in the D-loop 
and decrease in the copy number of mitochondrial DNA in human 
hepatocellular carcinoma. Mutat. Res., 547:71–78.
Lee, H.C. and Wei, Y.H. 2005. Mitochondrial biogenesis and mitochondrial 
DNA maintenance of mammalian cells under oxidative stress. Int. J. 
Biochem. Cell. Biol., 37:822–834.
Liu, S.L., Lin, X., Shi, D.Y. et al. 2002. Reactive oxygen species stimulated 
human hepatoma cell proliferation via cross-talk between 
PI3-K/PKB. and JNK signaling pathways. Arch. Biochem. Biophys., 
406:173–182.
Liu, V.W., Wang, Y., Yang, H.J. et al. 2003. Mitochondrial DNA variant 
16189T   C is associated with susceptibility to endometrial cancer. 
Hum. Mutat., 22:173–174.
Lutz, S., Weisser, H.J., Heizmann, J. et al. 1997. A third hypervariable region 
in the human mitochondrial D-loop. Hum. Genet., 101:384.
Mambo, E., Chatterjee, A., Xing, M. et al. 2005. Tumor-specific 
changes in mtDNA content in human cancer. Int. J. Cancer, 
116:920–924.
Oldenburg, R.A., Meijers-Heijboer, H., Cornelisse, C.J. et al. 2007. Genetic 
susceptibility for breast cancer: how many more genes to be found?. 
Crit. Rev. Oncol. Hematol., 63:125–149.
Parrella, P., Xiao, Y., Fliss, M. et al. 2001. Detection of mitochondrial DNA 
mutations in primary breast cancer and ﬁ  ne-needle aspirates. Cancer 
Res., 61:7623–7626.
Polyak, K., Li, Y., Zhu, H. et al. 1998. Somatic mutations of the 
mitochondrial genome in human colorectal tumours. Nat. Genet., 
20:291–293.
Porteous, W.K., James, A.M., Sheard, P.W. et al. 1998. Bioenergetic con-
sequences of accumulating the common 4977-bp mitochondrial DNA 
deletion. Eur. J. Biochem., 257:192–201.
Poulton, J., Luan, J., Macaulay, V. et al. 2002. Type 2 diabetes is associated 
with a common mitochondrial variant: evidence from a population-
based case-control study. Hum. Mol. Genet., 11:1581–1583.
Richard, S.M., Bailliet, G., Paez, G.L. et al. 2000. Nuclear and mitochondrial 
genome instability in human breast cancer. Cancer Res., 
60:4231–4237.
Rossignol, R., Faustin, B., Rocher, C. et al. 2003. Mitochondrial threshold 
effects. Biochem. J., 370:751–762.207
Review: Mitochondrial defects in breast cancer
Clinical Medicine: Oncology 2008:2 
Schwartz, SJr., Alazzouzi, H. and Perucho, M. 2006. Mutational dynamics 
in human tumors conﬁ  rm the neutral intrinsic instability of the mito-
chondrial D-loop poly-cytidine repeat. Genes Chromosomes Cancer, 
45:770–780.
Shadel, G.S. and Clayton, D.A. 1997. Mitochondrial DNA maintenance in 
vertebrates. Annu. Rev. Biochem., 66:409–435.
Taanman, J.W. 1999. The mitochondrial genome: structure, transcription, 
translation and replication. Biochim. Biophys. Acta., 
1410:103–123.
Tan, D.J., Bai, R.K. and Wong, L.J. 2002. Comprehensive scanning of 
somatic mitochondrial DNA mutations in breast cancer. Cancer Res., 
62:972–976.
Thibodeau, S.N., Bren, G. and Schaid, D. 1993. Microsatellite instability 
in cancer of the proximal colon. Science, 260:816–819.
Thompson, D. and Easton, D. 2004. The genetic epidemiology of breast 
cancer genes. J. Mammary Gland Biol. Neoplasia, 9:221–236.
Tseng, L.M., Yin, P.H., Chi, C.W. et al. 2006. Mitochondrial DNA mutations 
and mitochondrial DNA depletion in breast cancer. Genes Chromo-
somes Cancer, 45:629–638.
Wang, Y., Liu, V.W., Tsang, P.C. et al. 2006. Microsatellite instability in 
mitochondrial genome of common female cancers. Int. J. Gynecol. 
Cancer, 16 Suppl 1:259–266.
Warburg, O. 1930. The metabolism of tumors. London Constable Co Ltd.
Warburg, O. 1956. On the origin of cancer cells. Science, 123:309–314.
Weiderpass, E., Gridley, G., Persson, I. et al. 1997. Risk of endometrial and 
breast cancer in patients with diabetes mellitus. Int. J. Cancer, 
71:360–363.
Ye, C., Shu, X.O., Wen, W. et al. 2007. Quantitative analysis of mitochon-
drial DNA 4977-bp deletion in sporadic breast cancer and benign 
breast diseases. Breast Cancer Res. Treat., May 31 [Epub ahead of 
prin].
Yu, M., Zhou, Y., Shi, Y. et al. 2007. Reduced mitochondrial DNA copy 
number is correlated with tumor progression and prognosis in Chinese 
breast cancer patients. IUBMB. Life, 59:450–457.
Zhu, W., Qin, W., Bradley, P. et al. 2005. Mitochondrial DNA mutations in 
breast cancer tissue and in matched nipple aspirate ﬂ  uid. Carcino-
genesis, 26:145–152.
Zhu, W., Qin, W. and Sauter, E.R. 2004. Large-scale mitochondrial DNA 
deletion mutations and nuclear genome instability in human breast 
cancer. Cancer Detect. Prev., 28:119–126.